Combination of CBD and THC Cannabinoids Inhibit Glioma Brain Cancer Growth
News Mar 19, 2015
A recent compelling study published in the journal Molecular Cancer Therapeutics adds to the growing evidence that marijuana possesses medical properties and should be legally available for medicinal purposes.
Katherine A. Scott, Angus G. Dalgleish, and Wai M. Liu, who are affiliated with the Department of Oncology, Division of Clinical Sciences, St George’s, University of London, studied the effects of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) both by themselves and in combination with radiation therapy on glioma cells in-vitro and on laboratory mice.
Gliomas are a type of brain and spine cancer and are one of the most aggressive forms of cancer in humans. Gliomas takes its name from the glial cells of the brain and spine they originate in. Glial cells are the tissue that surrounds and supports neurons in the brain and spine, but the most glioma sites are in the brain.
The researchers found a good dose combination of 7mM (millimolar - a measure of amount-of-substance concentration) each of THC and CBD to minimize the psychoactive effects of the THC and still maintain their anti-cancer effectiveness. The researchers found in order to achieve a 50% kill rate of the glioma cancer cells they would have had to use 19mM of THC or 14mM of CBD if they were used separately, so using THC and CBD together was more effective.
The dose of radiation the researchers used had no dramatic effect on reducing tumor growth. The combination of THC and CBD without radiation was marginally more effective than radiation alone.
The combination of THC, CBD, and radiation basically stopped tumor growth in the mice for the rest of the study. Tumor sizes were significantly smaller in these the mice that received this combination of therapy in comparison to the other mice that did not.
The researchers noted that the combination of THC and CBD made the glioma cells more susceptible to the radiation because of an increase in markers of autophagy and apoptosis.
John Dickson from Kustomvape an Edinburgh company that sells CBD eliquid said “The benefits of CBD are getting reported around the world, this report is unusually because it also included the use of THC which is the part of marijuana that gets you ‘high’, so is not legally available in the UK. The consensus does seem to show that CBD is the most common beneficial marijuana compound with most benefits appearing when used alone and now in combination with THC.”
Kustomvape have had many of their customers report benefits from using their CBD eliquid, for instance Mrs Scott who suffers from Fibromyalgia and can have pains all over her body reported that since vaping Kustom hemp eLiquids her pain has eased. Mrs Scott explained that the CBD eliquid relaxed her muscles giving her relief from the constant pain and said she would recommend that anyone should try Kustom CBD Hemp Oil.
Fibromyalgia, also called fibromyalgia syndrome (FMS), is a long-term condition that causes pain all over the body.
As well as widespread pain, people with fibromyalgia may also have:
• increased sensitivity to pain
• fatigue (extreme tiredness)
• muscle stiffness
• difficulty sleeping
• problems with mental processes (known as "fibro-fog") - such as problems with memory and concentration
• irritable bowel syndrome (IBS) - a digestive condition that causes stomach pain and bloating
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE